ABSTRACT
Since March 2020, the COVID-19 pandemic has significantly reduced the availability of global aircraft-based observations (ABOs), which has been restored later in 2021. This study focuses on the impact of ABOs on a regional reanalysis. Indian Monsoon Data Assimilation and Analysis (IMDAA) is a regional reanalysis for a period from 1979 to 2020 (originally up to 2018) over India and surrounding regions produced at the National Centre for Medium Range Weather Forecasting (NCMRWF), India, in collaboration with the UK Met Office. A comparison of the impact of ABOs on other conventional and satellite observations assimilated in the NCMRWF global model and IMDAA during 2019 and 2020 revealed the importance of ABOs, particularly in IMDAA, since it did not assimilate the latest satellite data as the IMDAA system was frozen in October 2016. A data denial experiment that removes all the ABOs from the IMDAA assimilation system for a period from March to November 2019 is designed. The results from the IMDAA reanalysis run, which assimilates ABOs during the same period, are compared with the data denial experiment. Assimilation of ABOs strengthened the upper tropospheric circulation, the Tropical Easterly Jet (TEJ), during the Indian summer monsoon compared to the data denial experiment. Analysis of the features of two cyclones that developed over the North Indian Ocean during the study period revealed that ABO assimilation played a key role in simulating the track and intensity of these cyclones when they were in the ‘severe' category. Since the sample is small, more cyclone cases need to be analysed to consolidate the result. © 2023 Royal Meteorological Society.
ABSTRACT
Background: Post-acute sequelae of SARS-CoV-2 or long COVID, is characterized by persistence of symptoms and/or emergence of new symptoms post COVID-19 infection. As evidence accumulates and national initiatives arise to address this increasingly prevalent syndrome, characterization of specific patient groups is still lacking including patients with cancer. Using a nationally representative sample of over 4.3M COVID-19 patients from the National COVID Cohort Collaborative (N3C), we aim to describe characteristics of patients with cancer and long COVID. Methods: We employed two approaches to identify long COVID patients within N3C: i) patients presenting to a long COVID clinic at four N3C sites and ii) patients diagnosed using the recently introduced ICD-10 code: U09.9 Post COVID- 19 condition, unspecified. We included patients with at least one positive COVID-19 diagnosis between 1/1/2020 and 2/3/2022. Patients had to survive at least 90 days from the date of their COVID- 19 diagnosis. Analyses were performed in the N3C Data Enclave on the Palantir platform. Results: A total of 1700 adult patients with long COVID were identified from the N3C cohort;634 (37.3%) were cancer patients and 1066 were non-cancer controls. The most common represented cancers were skin (21.9%), breast (17.7%), prostate (8.3%), lymphoma (8.0%) and leukemia (5.7%). Median age of long-COVID cancer patients was 64 years (Interquartile Range: 54-72), 48.6% were 65 years or older, 60.4% females, 76.8% non-Hispanic White, 12.3% were Black, and 3% Hispanic. A total of 41.1% were current or former smokers, 27.7% had an adjusted Charlson Comorbidity Index score of 0, 18.6% score of 1 and 11.2% score of 2. A total of 57.2% were hospitalized for their initial COVID-19 infection, the average length of stay in the hospital was 9.6 days (SD: 16.7 days), 9.1% required invasive ventilation, and 13% had acute kidney injury during hospitalization. The most common diagnosis among the non-cancer long COVID patients was asthma (26%), diabetes (17%), chronic kidney disease (12%), heart failure (9.4%), and chronic obstructive pulmonary disease (7.8%). Among long COVID patients, compared to non-cancer controls, cancer patients were more likely to be older (OR = 2.4, 95%CI: 1.1-5.4, p = 0.03), have comorbidities (OR = 4.3, 95%CI: 2.9-6.2, p < 0.0001), and to be hospitalized for COVID-19 (OR = 1.3, 95%CI: 1.0-1.7, p = 0.05), adjusting for sex, race/ethnicity, body mass index and smoking history. Conclusions: In a nationally representative sample of long COVID patients, there was a relative overrepresentation of patients with cancer. Compared to non-cancer controls, cancer patients were older, more likely to have more comorbidities and to be hospitalized for COVID-19 warranting further investigation to identify risk factors for long COVID in patients with cancer.
ABSTRACT
Background: Patients with multiple myeloma (MM), an age-dependent neoplasm of antibody-producing plasma cells, have compromised immune systems due to multiple factors that may increase the risk of severe COVID-19. The NCATS' National COVID Cohort Collaborative (N3C) is a centralized data resource representing the largest multi-center cohort of ∼12M COVID-19 cases and controls nationwide. In this study, we aim to analyze risk factors associated with COVID-19 severity and death in MM patients using the N3C database. Methods: Our cohort included MM patients within the N3C registry diagnosed with COVID-19 based on positive PCR or antigen tests or ICD-10-CM. The outcomes of interest include all-cause mortality (including discharge to hospice) during the index encounter, and clinical indicators of severity (hospitalization/ED visit, use of mechanical ventilation, or extracorporeal membrane oxygenation/ECMO). Results: As of 09/10/2021, the N3C registry included 690371 cancer patients, out of which 17791 were MM patients (4707 were COVID-19+). The mean age at diagnosis was 65.9yrs, 57.6% were >65yo, 46.4% were females, and 21.8% were Blacks. 25.6% had a Charlson Comorbidity Index (CCI) score of ≥2. 55.6% required an inpatient or ED visit, and 3.65% required invasive ventilation. 11.4% developed acute kidney injury during hospitalization. Multivariate logistic regression analysis showed histories of pulmonary disease (OR 2.2;95%CI: 1.7-2.8), renal disease (OR 1.8;95%CI: 1.4-2.4), and black race (p<0.001) were associated with higher risk of severity. Interestingly, smoking status was significantly associated with a lower risk of severity (OR 0.7;95%CI: 0.5-0.9). Further, protective association was also observed between COVID-19 severity and blood or marrow transplant (BMT) (OR 0.52;95%CI: 0.4-0.7), daratumumab therapy (OR 0.64;95%CI: 0.42- 0.99) and COVID-19 vaccination (OR 0.28;95%CI: 0.18-0.44). IMiDs were associated increase in the risk of COVID-19 severity (OR 2.1;95%CI: 1.6-2.7). 2.3% of N3C-myeloma COVID-19+ patients died within the first 10 days, while 4.95% died within 30 days of COVID-19 hospitalization. Overall, the survival probability was 90.5% across the course of the study. Multivariate cox proportional hazard model showed that CCI score ≥2 (HR 4.4;95%CI: 2.2-8.8), hypertension (HR 1.6;95%CI: 1.02- 2.4), IMiD (HR 2.6;95%CI: 1.8-3.8) and proteasome inhibitor (HR 1.6;95%CI: 1.1-2.5) therapy were associated with worse survival. COVID-19 vaccination (HR 0.195;95%CI: 0.09-0.45) and BMT (HR 0.65;95%CI: 0.4-0.995) were associated with lower risk of death. Conclusions: We have identified previously unpublished potential risk factors for COVID-19 severity and death in MM as well as validated some published ones. To the best of our knowledge, this is the largest nationwide study on multiple myeloma patients with COVID-19.
ABSTRACT
Since time immemorial, natural products have found applications for the treatment of many maladies and ailments. This review attempts to portray the chemistry, bio-medical activities and efficacy in the therapy of COVID-19 of one age-old famous spice cumin and an eminent herb turmeric. Both of them have found significant applications in the disciplines of Ayurveda for their physiological and nutraceutical benefits. It is worth mentioning that the versatility of cumin and turmeric in terms of treating a variety of ailments, as well as their antioxidant properties, has always piqued the curiosity of the scientific community. Even in recent times, both of them are being scrutinised for their response to the global pandemic, COVID-19. Thymoquinone, the most abundant constituent of black cumin has shown immense therapeutic potential. On the other hand, curcumin, an important bio-active component of turmeric owns a wide array of pharmacologic effects. The utilisation of curcumin-derived carbon quantum dots and nanoparticle bound curcumin, on the other hand, is a new field in nanomedicine. Having said all these things, a few challenges have been encountered regarding their uses as drug candidates. Several research papers for the past fifteen years have been consulted using online databases like Google Scholar, Scopus and PubMed to compose this article in the viewpoint of the promises and challenges of the active constituents of cumin and turmeric as potential drug candidates.
ABSTRACT
Objective: To investigate the psychological strain experienced by orthopaedic healthcare workers and attributing factors during the COVID-19 pandemic. Methods: We surveyed healthcare workers in an outpatient musculoskeletal clinic with a questionnaire based on the validated Caregiver Strain Index1 . We have previously shown the prevalence of psychological strain during the pre-peak phase of the pandemic.2 The same group was followed up 6 months later (post-peak phase) to evaluate the downstream psychological strain. Results: Of the 57 participants who were followed up, 30 (52.6%) experienced a greater level of strain (Group A), similar to the prevalence in our previous study (51.6%). Significantly, participants in Group A work longer hours per day compared to Group B (8.8±1.6 vs. 8.0±1.5;mean difference, 0.8;95%CI, 0.0 to 1.6;p=0.043). “Family adjustments” (84.2%) garnered the most positive responses. Conclusion: Longer working hours contributes to psychological strain and measures should be designed to mitigate this. Potential impact on family life of healthcare workers is an unrecognised toll which should receive more attention. Health ministries should ensure measures to safeguard the mental health of healthcare workers to avoid reactive strategies during a pandemic. (Figure Presented).